Takeda's Entyvio Phase 3 Trial Shows Positive Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy TAK?
Source: Benzinga
- Phase 3 Clinical Data: Takeda Pharmaceutical's Entyvio (vedolizumab) demonstrated significant efficacy in the Phase 3 KEPLER trial for patients aged 2 to 17 with moderately to severely active ulcerative colitis, with 47.3% achieving clinical remission at week 54, potentially attracting interest from investors and healthcare professionals.
- Market Position Enhancement: More than one-third (34.7%) of patients achieved clinical remission at 14 weeks, and 29% attained sustained clinical remission at both 14 and 54 weeks, indicating that these positive outcomes could enhance Takeda's competitive position and drive further R&D investments.
- Stock Market Performance Analysis: Despite mixed overall market performance, Takeda's stock is trading 1.5% above its 20-day simple moving average, reflecting a positive short-term trend, with a 12% increase over the past 12 months.
- Technical Analysis Signals: The current RSI is at 50, indicating neutral territory, while the MACD at 0.10 is below its signal line of 0.15, suggesting bearish pressure on the stock; this combination of neutral RSI and bearish MACD indicates mixed momentum for Takeda's shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.750
Low
18.00
Averages
18.00
High
18.00
Current: 18.750
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
- Clinical Response Rate Increase: In the Phase 3 VERIFY study, the combination of Rusfertide and standard care more than doubled clinical response rates, exceeding 50%, indicating its significant potential in treating polycythemia vera.
- Good Safety and Tolerability: Rusfertide demonstrated good tolerability over 52 weeks, with injection site reactions at 47.4% and serious adverse events at only 8.1%, laying a solid foundation for its future market introduction.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for Rusfertide and granted Priority Review, with a decision expected in Q3 2024, which will expedite its market entry and address the urgent need for new therapies.
- Strengthened Partnership: The global licensing and collaboration agreement between Takeda and Protagonist will drive the commercialization of Rusfertide, enhancing both companies' ability to meet the treatment needs of patients with polycythemia vera.
See More
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
See More
Mental Health Treatment Market Set for Accelerated Growth
- Surging Market Demand: With over 970 million people affected by mental health disorders globally, the mental health therapeutics market is projected to exceed $40 billion in the coming years, indicating a strong demand for new treatment options, particularly in depression and anxiety.
- Clinical Milestone: Helus Pharma has appointed former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to its Board and as Chair of the Scientific Advisory Committee, leveraging her 40 years of experience to enhance the company's clinical development and regulatory strategy in the mental health sector.
- Innovative Drug Prospects: Compass Pathways' COMP360 has shown significant results in clinical trials for treatment-resistant depression, demonstrating efficacy in symptom reduction, which is expected to propel the company's further development in the mental health treatment market.
- Strategic Investment Opportunities: As large pharmaceutical companies seek to refresh their CNS drug pipelines, NSAs are viewed as a high-impact category with expansion potential, attracting investor attention towards clinical milestones and commercialization signals, indicating strong future returns.
See More
Mental Health Drug Market Set for Accelerated Growth
- Surging Market Demand: With over 970 million people affected by mental health disorders globally, the mental health therapeutics market is projected to exceed $40 billion in the coming years, highlighting a strong demand for new treatment options, particularly in depression and anxiety.
- Clinical Milestone: Helus Pharma has appointed former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to its Board and as Chair of the Scientific Advisory Committee, leveraging her 40 years of industry experience to drive clinical strategy and regulatory engagement in the development of novel serotonergic agonists (NSAs).
- Investment Appeal: As awareness of new serotonin therapies increases, NSAs are viewed as prime targets for acquisition and partnerships by large pharmaceutical companies, capable of supporting multiple indications and creating long-term investment return potential.
- Clear Regulatory Pathways: The Scientific Advisory Committee at Helus Pharma will provide leadership in clinical and regulatory governance, ensuring that patient outcomes and clinical rigor remain central to the company's growth strategy as it advances its drug pipeline.
See More
Takeda's Entyvio Phase 3 Trial Shows Positive Results
- Phase 3 Clinical Data: Takeda Pharmaceutical's Entyvio (vedolizumab) demonstrated significant efficacy in the Phase 3 KEPLER trial for patients aged 2 to 17 with moderately to severely active ulcerative colitis, with 47.3% achieving clinical remission at week 54, potentially attracting interest from investors and healthcare professionals.
- Market Position Enhancement: More than one-third (34.7%) of patients achieved clinical remission at 14 weeks, and 29% attained sustained clinical remission at both 14 and 54 weeks, indicating that these positive outcomes could enhance Takeda's competitive position and drive further R&D investments.
- Stock Market Performance Analysis: Despite mixed overall market performance, Takeda's stock is trading 1.5% above its 20-day simple moving average, reflecting a positive short-term trend, with a 12% increase over the past 12 months.
- Technical Analysis Signals: The current RSI is at 50, indicating neutral territory, while the MACD at 0.10 is below its signal line of 0.15, suggesting bearish pressure on the stock; this combination of neutral RSI and bearish MACD indicates mixed momentum for Takeda's shares.
See More
Positive Phase 3 Results for Vedolizumab in Pediatric Ulcerative Colitis
- Significant Clinical Remission: The KEPLER study demonstrated that 47.3% of the 120 participants achieved the primary endpoint of clinical remission at 54 weeks, indicating vedolizumab's efficacy in treating children aged 2 to 17, potentially providing a new treatment option for this difficult-to-treat population.
- Safety Profile Consistency: The results showed that vedolizumab's safety profile was generally consistent with its known safety in adults, with no new safety signals identified, suggesting that the drug's risk is manageable in pediatric patients, thereby enhancing confidence among clinicians and families.
- Expanded Treatment Options: This study offers new hope for pediatric and adolescent patients with ulcerative colitis, particularly those who have had inadequate responses to conventional therapies, which could change clinical practice and improve patient quality of life.
- Market Application Plans: Takeda plans to submit marketing applications for vedolizumab in the U.S. and EU, further advancing the drug's use in pediatric populations, reflecting the company's leadership in the field of inflammatory bowel disease.
See More
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
- Clinical Response Rate Increase: In the Phase 3 VERIFY study, the combination of Rusfertide and standard care more than doubled clinical response rates, exceeding 50%, indicating its significant potential in treating polycythemia vera.
- Good Safety and Tolerability: Rusfertide demonstrated good tolerability over 52 weeks, with injection site reactions at 47.4% and serious adverse events at only 8.1%, laying a solid foundation for its future market introduction.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for Rusfertide and granted Priority Review, with a decision expected in Q3 2024, which will expedite its market entry and address the urgent need for new therapies.
- Strengthened Partnership: The global licensing and collaboration agreement between Takeda and Protagonist will drive the commercialization of Rusfertide, enhancing both companies' ability to meet the treatment needs of patients with polycythemia vera.
See More
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
See More
Mental Health Treatment Market Set for Accelerated Growth
- Surging Market Demand: With over 970 million people affected by mental health disorders globally, the mental health therapeutics market is projected to exceed $40 billion in the coming years, indicating a strong demand for new treatment options, particularly in depression and anxiety.
- Clinical Milestone: Helus Pharma has appointed former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to its Board and as Chair of the Scientific Advisory Committee, leveraging her 40 years of experience to enhance the company's clinical development and regulatory strategy in the mental health sector.
- Innovative Drug Prospects: Compass Pathways' COMP360 has shown significant results in clinical trials for treatment-resistant depression, demonstrating efficacy in symptom reduction, which is expected to propel the company's further development in the mental health treatment market.
- Strategic Investment Opportunities: As large pharmaceutical companies seek to refresh their CNS drug pipelines, NSAs are viewed as a high-impact category with expansion potential, attracting investor attention towards clinical milestones and commercialization signals, indicating strong future returns.
See More
Mental Health Drug Market Set for Accelerated Growth
- Surging Market Demand: With over 970 million people affected by mental health disorders globally, the mental health therapeutics market is projected to exceed $40 billion in the coming years, highlighting a strong demand for new treatment options, particularly in depression and anxiety.
- Clinical Milestone: Helus Pharma has appointed former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to its Board and as Chair of the Scientific Advisory Committee, leveraging her 40 years of industry experience to drive clinical strategy and regulatory engagement in the development of novel serotonergic agonists (NSAs).
- Investment Appeal: As awareness of new serotonin therapies increases, NSAs are viewed as prime targets for acquisition and partnerships by large pharmaceutical companies, capable of supporting multiple indications and creating long-term investment return potential.
- Clear Regulatory Pathways: The Scientific Advisory Committee at Helus Pharma will provide leadership in clinical and regulatory governance, ensuring that patient outcomes and clinical rigor remain central to the company's growth strategy as it advances its drug pipeline.
See More
Takeda's Entyvio Phase 3 Trial Shows Positive Results
- Phase 3 Clinical Data: Takeda Pharmaceutical's Entyvio (vedolizumab) demonstrated significant efficacy in the Phase 3 KEPLER trial for patients aged 2 to 17 with moderately to severely active ulcerative colitis, with 47.3% achieving clinical remission at week 54, potentially attracting interest from investors and healthcare professionals.
- Market Position Enhancement: More than one-third (34.7%) of patients achieved clinical remission at 14 weeks, and 29% attained sustained clinical remission at both 14 and 54 weeks, indicating that these positive outcomes could enhance Takeda's competitive position and drive further R&D investments.
- Stock Market Performance Analysis: Despite mixed overall market performance, Takeda's stock is trading 1.5% above its 20-day simple moving average, reflecting a positive short-term trend, with a 12% increase over the past 12 months.
- Technical Analysis Signals: The current RSI is at 50, indicating neutral territory, while the MACD at 0.10 is below its signal line of 0.15, suggesting bearish pressure on the stock; this combination of neutral RSI and bearish MACD indicates mixed momentum for Takeda's shares.
See More
Positive Phase 3 Results for Vedolizumab in Pediatric Ulcerative Colitis
- Significant Clinical Remission: The KEPLER study demonstrated that 47.3% of the 120 participants achieved the primary endpoint of clinical remission at 54 weeks, indicating vedolizumab's efficacy in treating children aged 2 to 17, potentially providing a new treatment option for this difficult-to-treat population.
- Safety Profile Consistency: The results showed that vedolizumab's safety profile was generally consistent with its known safety in adults, with no new safety signals identified, suggesting that the drug's risk is manageable in pediatric patients, thereby enhancing confidence among clinicians and families.
- Expanded Treatment Options: This study offers new hope for pediatric and adolescent patients with ulcerative colitis, particularly those who have had inadequate responses to conventional therapies, which could change clinical practice and improve patient quality of life.
- Market Application Plans: Takeda plans to submit marketing applications for vedolizumab in the U.S. and EU, further advancing the drug's use in pediatric populations, reflecting the company's leadership in the field of inflammatory bowel disease.
See More
